<DOC>
	<DOCNO>NCT00413010</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy pregabalin compare placebo treatment patient general anxiety disorder ( GAD ) . Efficacy measure improvement total Hamilton Anxiety Rating Scale ( HAM-A ) score baseline observe follow 8 week double-blind treatment early termination double-blind treatment phase analyze use mixed linear model repeat measure .</brief_summary>
	<brief_title>Pregabalin Treatment Patients With Generalized Anxiety Disorder ( GAD ) .</brief_title>
	<detailed_description>Further enrollment study stop January 28 , 2008 base recommendation independent data monitoring committee . The recommendation stop study base safety finding .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Adult male female subject primary DSMIV diagnosis GAD , confirm MINI structure interview . Historical failure respond optimally GAD treatment Current primary DSMIV ( Diagnostic Statistical Manual Mental Disorders 4th edition ) diagnosis major depressive disorder without seasonal pattern , dysthmic disorder , depressive disorder NOS ( otherwise specify ) , social phobia , panic disorder without agoraphobia , post traumatic stress disorder , dissociative disorder , borderline personality disorder , obsessivecompulsive disorder , antisocial personality disorder , define DSMIV TR ( Diagnostic Statistical Manual Mental Disorders 4th edition , Text Revision ) . Past and/or current DSMIV diagnosis schizophrenia , schizoaffective disorder , psychotic disorder , bipolar disorder ( I II ) , factitious disorder cognitive disorder ( include delirium , dementia , amnestic disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>